688 reports of this reaction
2.2% of all PANITUMUMAB reports
#10 most reported adverse reaction
NEUROPATHY PERIPHERAL is the #10 most commonly reported adverse reaction for PANITUMUMAB, manufactured by Amgen, Inc. There are 688 FDA adverse event reports linking PANITUMUMAB to NEUROPATHY PERIPHERAL. This represents approximately 2.2% of all 31,648 adverse event reports for this drug.
Patients taking PANITUMUMAB who experience neuropathy peripheral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROPATHY PERIPHERAL is a less commonly reported adverse event for PANITUMUMAB, but still significant enough to appear in the safety profile.
In addition to neuropathy peripheral, the following adverse reactions have been reported for PANITUMUMAB:
The following drugs have also been linked to neuropathy peripheral in FDA adverse event reports:
NEUROPATHY PERIPHERAL has been reported as an adverse event in 688 FDA reports for PANITUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROPATHY PERIPHERAL accounts for approximately 2.2% of all adverse event reports for PANITUMUMAB, making it a notable side effect.
If you experience neuropathy peripheral while taking PANITUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.